Kiora Pharmaceuticals
Dirigeants
Voir l'organigramme avec ses 10 principaux dirigeants
Biographies les plus recherchées chez Kiora Pharmaceuticals
- Brian Strem, Director, President and Chief Executive Officer
- Praveen Tyle, Chairman of the Board
- Aron Shapiro, Director
Changements de dirigeants chez Kiora Pharmaceuticals
- Praveen Tyle qui était Director, devient Chairman of the Board (publié le 27 septembre 2023).
- Paul Chaney, qui est Chairman of the Board, part en retraite (publié le 27 septembre 2023).
Créer une alerte
pour suivre les mouvements de dirigeants chez Kiora Pharmaceuticals.
Pharmacie
Kiora Pharmaceuticals a 1 863 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Johnson & Johnson (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- AstraZeneca has announced the acquisition of Fusion Pharma (publié le 23 mars 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publié le 19 mars 2024).
- Frontier Medicines vient d'annoncer une levée de fonds de 80 millions de dollars. (publié le 27 février 2024).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Kiora Pharmaceuticals
- The Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
- Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
- Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
- Association for Research in Vision and Ophthalmology (ARVO)
- Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
- Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases
- Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye
- Kiora Investor Webcast
- Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
- Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clini
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Kiora Pharmaceuticals
- Kiora Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Kiora Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Brian Strem 
Appelez Kiora Pharmaceuticals au +1 781...
